Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial

Table 1 General characteristics of MASLD patients at baseline

Variable	Placebo group (n = 23)	Vitamin D group (n = 23)	P value^*
Age (y)	43.9 ± 11.0	47.3 ± 9.4	0.26
Weight (kg)	89.3 ± 13.0	86.0 ± 17.8	0.47
BMI (kg/m²)	33.0 ± 10.5	30.3 ± 4.4	0.26
WC (cm)	109.7 ± 10.9	108.1 ± 12.3	0.65
Female (%)	47.8	52.2	0.77
Married (%)	82.6	87.0	0.53
Educated (%)	95.7	95.7	0.99
Vitamin D deficiency (< 30ng/ml) (%)	43.5	52.8	0.55
MASLD grade (by B-ultrasound) (%)			0.54
Grade 2	60.9	69.6
Grade 3	39.1	30.4
Medication use (%)
NSAIDs	4.3	4.3	0.99
Anti-acids	8.7	8.7	0.99
Corticosteroids	4.3	0	0.31
OHAs	13.0	21.7	0.44
Livergol	8.7	26.1	0.12
Statins^†	13.0	39.1	0.04
Ursodeoxycholic acid	0	8.7	0.15
Anti-hypertensive	17.3	13.0	0.68
Dietary supplement use (%)
Vitamin E	8.7	17.4	0.38
Iron-folate	8.7	0	0.15
Calcium	4.3	0	0.31
Multi vitamin	0	4.3	0.31
Omega-3	4.3	0	0.31

Values are presented as mean ± standard deviation except those are presented as percent
^*Based on independent samples t-tests for quantitative variables and chi-square for qualitative variables
MASLD: Metabolic Dysfunction–Associated Liver Disease; BMI: Body Mass Index; WC: Waist Circumference
^†Statistically significant differences between two groups was seen

ISSN: 1475-2891